Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Relamorelin · 1 trial · 1 indication
Calculation of gastric volume by single photon emission computed tomography (SPECT)
Measurement of satiety by completion of the Hunger/Satiety questionnaire after ingesting a nutrient drink
Measurement of gastric motility by gastroduodenal manometry
| Arm | Type | Description |
|---|---|---|
| Relamorelin | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Relamorelin | DRUG | Double blind RM-131 will be delivered three times by injection during the course of the study |
| Placebo | DRUG | Double blind Placebo will be delivered three times by injection during the course of the study |
Inclusion Criteria: 1. Able to provide written informed consent prior to any study procedures, and be willing and able to comply with study procedures 2. No medical problems or chronic diseases, specifically, no type 2 diabetes mellitus 3. Body mass index of 18-35 kg/m² 4. Female subjects must have...
Relamorelin is an investigational small molecule being developed for gastric motility, a gastrointestinal condition. It is intended to affect stomach function, though it is not yet approved and remains in clinical development.
Relamorelin is being developed by Rhythm Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol RYTM.
Relamorelin is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Its only clinical trial to date has been completed.
Relamorelin has one completed Phase 1 trial, NCT02466711, which studied its effect on satiation, gastric volume, gastric accommodation, and distal gastric function in healthy volunteers in the United States. The trial enrolled 16 participants and was randomized, double-blind, and placebo-controlled.
No alternative names for Relamorelin have been disclosed. It is identified by its single name in clinical development.